Impact of clinical pharmacist interventions in psychiatric hospitals on clinical and medication-related outcomes: a systematic review and meta-analysis
- 1Department of Pharmacology, Faculty of Medicine Maribor, University of Maribor
- 2Department of Clinical Pharmacy, Ormoz Psychiatric Hospital
- 3Faculty of Pharmacy, University of Ljubljana
Abstract
Introduction: Clinical pharmacist interventions have been shown to improve outcomes and reduce drug-related problems (DRPs) in patients with mental disorders. However, no previous meta-analysis has comprehensively evaluated their effectiveness in reducing DRPs and optimizing pharmacotherapy in psychiatric inpatient settings.
Aim: To evaluate the effectiveness of clinical pharmacist interventions in psychiatric inpatient settings on DRPs and clinical outcomes among patients with mental disorders.
Methods: This systematic review and meta-analysis was conducted according to the PRISMA 2020 statement and prospectively registered in PROSPERO (CRD420261309290). PubMed, Scopus, CENTRAL, and CINAHL were searched from inception to March 2026. Eligible studies included adult psychiatric inpatients receiving clinical pharmacist interventions, including different pharmaceutical services, such as medication review, medication reconciliation, and ward round participation. A meta-analysis was performed in R using a random-effects model. Heterogeneity was calculated using I ² . Random-effects meta-analyses were performed for DRPs, potentially inappropriate medications (PIMs), and the number of prescribed medications. Risk of bias was assessed using RoB two and ROBINS-I.
Results: Eighteen studies met the inclusion criteria, including one randomized controlled trial and 17 non-randomized interventional studies. Clinical pharmacist interventions significantly reduced the number of prescribed medications (mean difference −1.0 medications per patient, (95% CI −1.5 to −0.5) and were associated with a pooled reduction in DRPs of 70.7% (95% CI 46.5–87.0), as well as reductions in PIMs. Evidence for patient-centred clinical outcomes, including symptom improvement, quality of life, and healthcare utilization, remained limited. Substantial heterogeneity was observed across studies, reflecting differences in intervention types, patient populations, and outcome measures. Most non-randomized studies were judged to have a serious risk of bias because of confounding and uncontrolled study designs.
Conclusion: Clinical pharmacist interventions in psychiatric inpatient settings improve medication-related outcomes by reducing DRPs, PIMs, and the number of prescribed medications. These findings support the integration of clinical pharmacists into multidisciplinary psychiatric teams. Further adequately powered multicentre randomized controlled trials are needed to determine whether these improvements translate into better long-term patient-centred clinical outcomes.
Related
- A Structured, Auditable Taxonomy for Pharmacist-Identifiable Medication-Related Risk Signals in Routine Admission Data: A Retrospective Medication Safety Audit in a High-Risk Inpatient Cohort
- Independent effects of companion lifestyle interventions in anti-obesity medication trials: protocol of a systematic review and meta-analysis
- The Patient Perspectives of Clinical Pharmacist Services in Hospitals and Clinics: A Focused Narrative Review of Qualitative Studies.
- Adherence of HIV/AIDS patients following Medication Therapy Management and Pharmacist Counselling at a Public Hospital in Yogyakarta, Indonesia
- Beyond words: Enhancing medication understanding with pictograph-integrated pharmacist counseling in linguistically diverse patients
BibTeX
@article{stuhec2026impact,
title = {{Impact of clinical pharmacist interventions in psychiatric hospitals on clinical and medication-related outcomes: a systematic review and meta-analysis}},
author = {Matej Stuhec and Kaja Balasko and Anteja Gorjan Gazdag and Zala Cuk and Igor Locatelli},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1945082},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1945082/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Impact of clinical pharmacist interventions in psychiatric hospitals on clinical and medication-related outcomes: a systematic review and meta-analysis
AU - Matej Stuhec
AU - Kaja Balasko
AU - Anteja Gorjan Gazdag
AU - Zala Cuk
AU - Igor Locatelli
PY - 2026
DA - 2026/10/08
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1945082
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1945082/full
AB - Introduction: Clinical pharmacist interventions have been shown to improve outcomes and reduce drug-related problems (DRPs) in patients with mental disorders. However, no previous meta-analysis has comprehensively evaluated their effectiveness in reducing DRPs and optimizing pharmacotherapy in psychiatric inpatient settings. Aim: To evaluate the effectiveness of clinical pharmacist interventions in psychiatric inpatient settings on DRPs and clinical outcomes among patients with mental disorders. Methods: This systematic review and meta-analysis was conducted according to the PRISMA 2020 statement and prospectively registered in PROSPERO (CRD420261309290). PubMed, Scopus, CENTRAL, and CINAHL were searched from inception to March 2026. Eligible studies included adult psychiatric inpatients receiving clinical pharmacist interventions, including different pharmaceutical services, such as medication review, medication reconciliation, and ward round participation. A meta-analysis was performed in R using a random-effects model. Heterogeneity was calculated using I ² . Random-effects meta-analyses were performed for DRPs, potentially inappropriate medications (PIMs), and the number of prescribed medications. Risk of bias was assessed using RoB two and ROBINS-I. Results: Eighteen studies met the inclusion criteria, including one randomized controlled trial and 17 non-randomized interventional studies. Clinical pharmacist interventions significantly reduced the number of prescribed medications (mean difference −1.0 medications per patient, (95% CI −1.5 to −0.5) and were associated with a pooled reduction in DRPs of 70.7% (95% CI 46.5–87.0), as well as reductions in PIMs. Evidence for patient-centred clinical outcomes, including symptom improvement, quality of life, and healthcare utilization, remained limited. Substantial heterogeneity was observed across studies, reflecting differences in intervention types, patient populations, and outcome measures. Most non-randomized studies were judged to have a serious risk of bias because of confounding and uncontrolled study designs. Conclusion: Clinical pharmacist interventions in psychiatric inpatient settings improve medication-related outcomes by reducing DRPs, PIMs, and the number of prescribed medications. These findings support the integration of clinical pharmacists into multidisciplinary psychiatric teams. Further adequately powered multicentre randomized controlled trials are needed to determine whether these improvements translate into better long-term patient-centred clinical outcomes.
SN - 1663-9812
ER -